A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Cherry Thomas, MD
Wugen, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Peter Maccallum Cancer Center
Melbourne, Australia
- Royal Perth Hospital
Perth, Australia
- Royal Prince Alfred Hospital
Sydney, Australia
- City of Hope
Duarte, California, United States
- Stanford Healthcare
Palo Alto, California, United States
- Norton Health Care
Louisville, Kentucky, United States
- University of Maryland
Baltimore, Maryland, United States
- Washington University
St Louis, Missouri, United States
- Providence Portland Medical Center
Portland, Oregon, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Jul 2023
- Primary completion
- 8 Oct 2024
- Completion
- 8 Oct 2024
- Last update posted
- 30 Sept 2025
- Registered enrollment
- 9
- Registry id
- NCT05470140
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.